Eastern Bank Boosts Stake in Royalty Pharma PLC $RPRX

Eastern Bank lifted its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 1,368.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 371,255 shares of the biopharmaceutical company’s stock after purchasing an additional 345,968 shares during the quarter. Eastern Bank owned about 0.06% of Royalty Pharma worth $13,098,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of RPRX. Swedbank AB boosted its stake in Royalty Pharma by 0.4% during the third quarter. Swedbank AB now owns 12,200,270 shares of the biopharmaceutical company’s stock worth $430,426,000 after buying an additional 42,800 shares during the period. State Street Corp lifted its holdings in shares of Royalty Pharma by 7.1% in the 2nd quarter. State Street Corp now owns 10,194,938 shares of the biopharmaceutical company’s stock worth $367,324,000 after acquiring an additional 678,810 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Royalty Pharma by 2.2% during the 2nd quarter. Geode Capital Management LLC now owns 8,176,504 shares of the biopharmaceutical company’s stock worth $299,494,000 after purchasing an additional 177,036 shares during the period. Norges Bank acquired a new stake in Royalty Pharma in the 2nd quarter valued at approximately $181,388,000. Finally, Patient Capital Management LLC raised its position in Royalty Pharma by 0.5% in the second quarter. Patient Capital Management LLC now owns 2,987,988 shares of the biopharmaceutical company’s stock valued at $107,657,000 after purchasing an additional 15,342 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently commented on RPRX. Leerink Partners set a $45.00 price target on Royalty Pharma in a research report on Thursday, December 11th. Morgan Stanley cut their target price on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. TD Cowen upped their price objective on Royalty Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Cowen reiterated a “buy” rating on shares of Royalty Pharma in a report on Thursday, December 11th. Finally, Weiss Ratings downgraded Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $45.60.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $40.36 on Wednesday. The company has a market cap of $23.30 billion, a P/E ratio of 30.58, a PEG ratio of 1.93 and a beta of 0.43. The firm has a fifty day moving average price of $39.30 and a 200 day moving average price of $37.36. The company has a current ratio of 3.48, a quick ratio of 3.48 and a debt-to-equity ratio of 0.89. Royalty Pharma PLC has a 12 month low of $29.66 and a 12 month high of $41.70.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.06. The company had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%. Sell-side analysts predict that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 20th will be issued a $0.235 dividend. This represents a $0.94 dividend on an annualized basis and a yield of 2.3%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Friday, February 20th. Royalty Pharma’s dividend payout ratio is currently 66.67%.

Insider Activity at Royalty Pharma

In related news, CFO Terrance P. Coyne sold 69,594 shares of Royalty Pharma stock in a transaction on Monday, November 17th. The shares were sold at an average price of $39.30, for a total transaction of $2,735,044.20. Following the sale, the chief financial officer directly owned 54,760 shares in the company, valued at $2,152,068. This trade represents a 55.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP George W. Lloyd sold 132,426 shares of the business’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $38.34, for a total transaction of $5,077,212.84. The SEC filing for this sale provides additional information. Insiders sold 936,093 shares of company stock worth $36,499,945 over the last quarter. 18.90% of the stock is currently owned by insiders.

Key Stories Impacting Royalty Pharma

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Company raised its quarterly dividend to $0.235, which can boost yield and appeal to income-focused investors and signals confidence in cash generation. Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.235
• Positive Sentiment: Royalty struck a deal with Teva on a potential vitiligo drug, adding a new partnered asset that could generate future royalties if successful — positive for pipeline diversification and long‑term royalty upside. Teva inks deal with Royalty Pharma on potential vitiligo drug
• Positive Sentiment: Management presented a business update at the J.P. Morgan Healthcare Conference—provides transparency on deal flow, portfolio performance and near‑term catalysts that can support investor confidence. Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: Full transcript of the J.P. Morgan presentation is available — useful for parsing management commentary for guidance or deal timing, but the transcript itself doesn’t change fundamentals. Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Reported short interest data appears anomalous (zeros/NaN) and likely reflects a reporting glitch rather than a substantive change in short positioning; not a clear driver of price.
• Negative Sentiment: CFO Terrance P. Coyne sold 69,582 shares (≈$2.67M) in early January, reducing his stake materially — large insider sales can be interpreted as profit‑taking or reduced insider conviction and often pressures sentiment. SEC Form 4 (Terrance P. Coyne)
• Negative Sentiment: EVP Marshall Urist sold 20,000 shares (~$815.6k) on Jan. 9, trimming his position by 25%—another sizeable insider sale that may add short‑term selling pressure. SEC Form 4 (Marshall Urist)

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.